High-risk localised prostate cancer: Multimodal treatment strategies combining neoadjuvant hormonal therapy and/or chemotherapy with radical prostatectomy

Expert Opinion on Emerging Drugs

Volumn 8, Issue 2, 2003, Pages 291-295

  Eastham, James A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chemotherapy; Prostate cancer; Radical prostatectomy

Indexed keywords

ANTIANDROGEN; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; CORTICOSTEROID; DOCETAXEL; ERYTHROPOIETIN; ESTRAMUSTINE; ETOPOSIDE; HYDROCORTISONE; MITOXANTRONE; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; VINBLASTINE; WARFARIN;

BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; GRANULOCYTOPENIA; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; MALE; NEUTROPENIA; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REVIEW; THROMBOEMBOLISM; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HUMANS; MALE; NEOADJUVANT THERAPY; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RISK ASSESSMENT;

EID: 0346996941     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.8.2.291     Document Type: Review

References (23)

1. PARTIN AW, KATTAN MW, SUBONG EN et al.: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multiinstitutional update. JAMA (1997) 277(18):1445-1451.
2. ROACH M 3RD, MARQUEZ C, YUO HS et al.: Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. (1994) 28(1):33-37.
3. KATTAN MW, EASTHAM JA, STAPLETON AM, WHEELER TM, SCARDINO PT: A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J. Natl. Cancer Inst. (1998) 90(10):766-771.
4. GRAEFEN M, KARAKIEWICZ PI, CAGIANNOS I et al.: International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J. Clin. Oncol. (2002) 20(15):3206-3612.
5. BLANCO F JR, KATTAN MW, SCARDINO PT, POWELL IJ, PONTES EJ, WOOD DP JR: Radical prostatectomy nomograms in black American men: accuracy and applicability. J. Urol (2003) 170(1):73-76; discussion 76-77.
6. BOLLA M, GONZALEZ D, WARDE P et al.: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N. Engl. J. Med. (1997) 337(5):295-300.
7. SCOLIERI MJ, ALTMAN A, RESNICK MI: Neoadjuvant hormonal ablative therapy before radical prostatectomy: a review. Is it indicated? J. Urol. (2000) 164(5):1465-1472.
8. WITJES WP, SCHULMAN CC, DEBRUYNE FM: Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 NO MO prostatic carcinoma. The European Study Group on Neoadjuvant Treatment of Prostate Cancer. Urology (1997) 49:65-69.
9. TANNOCK IF, OSOBA D, STOCKLER MR et al.: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol. (1996) 14(6):1756-1764.
10. KANTOFF PW, HALABI S, CONAWAY M et al.: Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J. Clin. Oncol. (1999) 17(8):2506-2513.
11. HUDES GR, NATHAN F, KHATER C et al.: Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J. Clin. Oncol. (1997) 15(9):3156-3163.
12. PETRYLAK DP, MACARTHUR R, O'CONNOR J et al.: Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone refractory prostate cancer. Semin. Oncol. (1999) 26(5 Suppl. 17):28-33.
13. SINABALDI VJ, CARDUCCI M, LAUFER M, EISENBERGER M: Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer. Semin. Oncol. (1999) 26(5 Suppl. 17):45-48.
14. PIENTA KJ, REDMAN B, HUSSAIN M et al.: Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J. Clin. Oncol. (1994) 12(10):2005-2012.
15. KELLY WK, CURLEY T, SLOVIN S et al.: Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J. Clin. Oncol. (2001) 19(1);:44-53.
16. PICUS J, SCHULTZ M: Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer. preliminary results. Semin. Oncol. (1999) 26(5 Suppl. 17):14-18.
17. BERRY W, GREGURICH M, DAKHIL S, HATHORN J, ASMAR L: Phase II randomized trial of weekly paclitaxel with or without estramustine phosphate in patients with symptomatic, hormone-refractory, metastatic prostate cancer. Am. Soc. Clin. Oncol. (2001) Abstract 696.
18. BEER TM, HOUGH KM, GARZOTTO M et al: Treatment of androgen-independent prostate cancer with weekly high-dose calcitriol and docetaxel. Am. Soc. Clin. Oncol. (2001) Abstract 2369.
19. SAVARESE DM, HALABI S, HARS V et al: Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.J. Clin. Oncol. (2001) 19(9):2509-2516.
20. CLARK PE, PEEREBOOM DM, DREICER R, LEVIN HS, CLARK SB, KLEIN EA: Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology (2001) 57(2):281-285.
21. PETTAWAY CA, PISTERS LL, TRONCOSO P et al: Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. J. Clin. Oncol. (2000) 18(5):1050-1057.
22. KONETY BR, EASTHAM J, SCARDINO PT et al.: Radical prostatectomy following neo-adjuvant chemo-hormonal therapy for high-risk or locally advanced prostate cancer: a Phase I/II study. J. Urol. (2003) (In Press).
23. EASTHAM JA, KELLY WK, GROSSFELD GD, SMALL E: CALGB Trial 90203: randomized Phase III study of radical prostatectomy alone versus estramustine and docetaxel prior to radical prostatectomy for patients with high-risk localized disease. Urology (2003) (In Press).